|Bid||346,000.00 x 0|
|Ask||346,500.00 x 0|
|Day's Range||342,000.00 - 352,000.00|
|52 Week Range||241,500.00 - 474,000.00|
|Beta (3Y Monthly)||1.04|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 21, 2019 - Oct 26, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||499,500.00|
A South Korean court approved arrest warrants on Saturday for two executives at Samsung Electronics Co Ltd over their alleged roles in a suspected accounting fraud at the biotech arm of Samsung Group. The Seoul Central District Court said in a statement it had granted warrants to arrest the executives due to concerns over possible destruction of evidence. Two Samsung Electronics officials were also arrested on suspicion of destroying evidence earlier this month.
A South Korean court said on Saturday it had approved warrants to arrest two senior officials at Samsung Electronics in relation to an alleged accounting fraud at the tech giant's biopharma affiliate. The Seoul Central District Court said in a statement it had granted warrants to arrest the officials suspected of destroying evidence in the case. Prosecutors accused the two Samsung Electronics officials of ordering employees at biopharmaceutical firm Samsung BioLogics to destroy internal documents, as authorities looked into an alleged violation of accounting rules at the BioLogics, according to local media reports.
South Korean prosecutors raided Korea Exchange as part of an investigation into Samsung BioLogics' suspected violation of accounting rules, a bourse official said on Friday. In November, the country's financial watchdog said the biotech arm of Samsung Group intentionally breached accounting rules ahead of its 2016 listing and reported the case to prosecutors. Prosecutors raided the head office of Samsung BioLogics in December as part of their criminal probe into alleged accounting fraud.
A South Korean court has suspended the financial regulator's disciplinary action against Samsung BioLogics Co Ltd for allegedly breaching accounting rules, an official at the Seoul Administrative Court said on Tuesday. In November, the Financial Services Commission (FSC) said the biotech arm of Samsung Group intentionally breached accounting rules ahead of its 2016 listing.
Jan 7 (Reuters) - Samsung Bioepis, a joint venture between Samsung BioLogics and Biogen, in a press release: * SAYS FORMS PARTNERSHIP WITH CHINESE BIOPHARMA 3SBIO Further company coverage:
Samsung BioLogics Co Ltd's on Thursday said its head office has been raided by South Korean prosecutors as part of a criminal probe into alleged accounting fraud. The Financial Services Commission last month filed a complaint against the biotech arm of conglomerate Samsung Group, saying it intentionally breached accounting rules ahead of its 2016 listing. Samsung BioLogics denied wrongdoing and filed an administrative lawsuit against the regulator.
South Korea's main stock exchange has decided Samsung BioLogics Co Ltd is qualified to continue trading on the exchange and that the company's shares will resume trading on Tuesday, the bourse said on Monday. "We concluded that there was no serious concern about the company's continuity regarding its business outlook, order backlogs and order plans, as the company's revenues and profitability were found to have improved," the Korea Exchange said in a statement. Samsung BioLogics said in a statement it would strengthen its internal control system and planned to prove the legitimacy of its accounting methods.
South Korea's bourse operator said it will begin a formal review on whether to delist shares of Samsung BioLogics over alleged violation of accounting rules. Once the formal review begins, the bourse plans to decide by the end of December whether the company will be delisted or not, the Korea Exchange said in a statement on Friday. Trading in shares of Samsung BioLogics, the biotech drug arm of South Korea's top conglomerate - Samsung Group, has been suspended since Nov. 14, immediately after the financial regulator said the company had intentionally breached accounting rules ahead of its listing in 2016.
South Korea's top financial regulator said Samsung BioLogics Co Ltd had intentionally breached accounting rules ahead of its 2016 listing, leading to a suspension in trading of the biotech firm's shares and a review of its listing status. The Financial Services Commission (FSC), which has been reviewing the matter after a complaint by an activist group and politicians that the Samsung Group arm unfairly inflated its value, also called for Samsung BioLogics' CEO to be fired. The disciplinary action is a blow to South Korea's biggest conglomerate, which is banking on biopharmaceuticals for growth and announced plans in August to invest 25 trillion won ($22 billion) in the business and in other areas such as artificial intelligence and 5G mobile technology.
A securities panel of South Korea’s Financial Services Commission said Wednesday Samsung Biologics Co. deliberately overstated the value of affiliate Samsung Bioepis ahead of its IPO in 2016, which raised about $2 billion. The regulator fined Samsung Biologics 8 billion won ($7 million) and recommended the company dismiss its CEO.
Round-up of South Korean financial markets: ** South Korea's KOSPI stock index edged lower on Wednesday as investors favoured caution while awaiting financial regulator's decision on alleged violation ...
Shares in Samsung BioLogics Co Ltd plunged on Monday amid concerns about its accounting practices ahead of a meeting of regulators this week to review whether it has violated rules which could lead to its delisting. The biotech drug arm of Samsung Group, South Korea's biggest family-run conglomerate, fell 16 percent by 0425 GMT, wiping 3.9 trillion won ($3.5 billion) off its market value after South Korean media reported that regulators were expected to reach a conclusion about the case at a meeting on Wednesday. An official at South Korea's top corporate watchdog, the Financial Services Commission (FSC), could not confirm the reports.